Pharmaceuticals

Global Idefirix Market 2026–2035 advancing transplant therapy solutions

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Idefirix Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The historical growth observed can be attributed to several factors, including the scarcity of organs available for kidney transplantation and the widespread presence of donor-specific antibodies. The limitations of conventional desensitization methods also played a role, alongside the early positive clinical results seen with imlifidase, and an increase in the number of transplant centers.

Anticipated expansion during the forecast period is driven by increased demand for kidney transplants, a broadening of transplant waiting lists, the wider adoption of precision immunology, supportive regulatory frameworks, and the proliferation of specialized transplant clinics.

Prominent trends projected for the forecast horizon encompass the rising application of desensitization therapies in transplantation, an increasing focus on highly sensitized patients, the expansion of enzyme-based immunomodulation, higher kidney transplant volumes, and improved access to advanced transplant care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp

What Drivers Are Influencing The Idefirix Market?

The rising occurrence and new cases of kidney conditions are anticipated to drive the future expansion of the idefirix market. Kidney diseases refer to ailments that harm the kidneys’ operational capacity or physical makeup, impeding their essential roles in waste filtration and fluid regulation within the body. The growing number of existing and new kidney disease cases stems from various factors, including an older demographic, increasing instances of diabetes and high blood pressure, lifestyle decisions, and inherited susceptibilities. Idefirix, an innovative enzyme therapy that breaks down immunoglobulin G (IgG), assists kidney disease sufferers by allowing highly sensitized patients to receive vital kidney transplants. It achieves this by efficiently diminishing donor-specific antibodies that would typically lead to rejection. For instance, a report from June 2023 by Kidney Research, a UK-based research body, forecasts a rise in acute kidney injury cases, from approximately 615,000 in 2022 to 637,000 by 2033. Consequently, the expanding occurrence and new cases of kidney illnesses are fueling the growth of the idefirix market.

What Major Segment Divisions Exist Within The Idefirix Market?

The idefirix market covered in this report is segmented –

1) By Patient Demographics: Pediatric Patients, Adult Patients

2) By Application: Kidney Transplantation, Desensitization Protocols

3) By End-User: Hospitals, Specialized Clinics, Home Healthcare

4) By Distribution Channel: Direct Sales, Pharmacies

How Are Trends Shaping The Direction Of The Idefirix Market?

A primary focus within the idefirix market involves creating novel approaches, specifically desensitization treatment, aimed at reducing sensitivity in highly sensitized kidney transplant patients. This medical procedure, known as desensitization treatment, works by eliminating or diminishing detrimental antibodies, thereby allowing transplant recipients to accept organs from donors with whom they are otherwise incompatible. An example illustrating this is Hansa Biopharma, a biopharmaceutical firm based in Sweden, announcing in July 2023 that Idefirix (imlifidase) received approval from the Australian Therapeutic Goods Administration (TGA), Australia’s regulatory body, for use as a desensitization treatment for highly sensitized kidney transplant patients. Such approval makes it possible for these patients to undergo kidney transplants using organs from both living and deceased donors. The mechanism of this treatment involves decreasing or eradicating harmful anti-donor antibodies, which would otherwise hinder successful transplantation. Driven by encouraging outcomes from Hansa Biopharma’s phase 2 studies, this sanction represents a crucial advancement in enhancing kidney transplant possibilities for highly sensitized individuals in Australia.

Which Companies Are Leading Innovation In The Idefirix Market?

Major companies operating in the idefirix market are Hansa Biopharma AB

Read the full idefirix market report here:

https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Idefirix Market?

Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Idefirix Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20093&type=smp

Browse Through More Reports Similar to the Global Idefirix Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795